NZ527144A - 2H-1-benzopyran derivatives, processes for their preparation and pharmaceutical compositions thereof - Google Patents
2H-1-benzopyran derivatives, processes for their preparation and pharmaceutical compositions thereofInfo
- Publication number
- NZ527144A NZ527144A NZ527144A NZ52714402A NZ527144A NZ 527144 A NZ527144 A NZ 527144A NZ 527144 A NZ527144 A NZ 527144A NZ 52714402 A NZ52714402 A NZ 52714402A NZ 527144 A NZ527144 A NZ 527144A
- Authority
- NZ
- New Zealand
- Prior art keywords
- alkyl
- compound
- phenyl
- alkanoyl
- atoms
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 59
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 7
- 125000000850 2H-chromenyl group Chemical class O1C(C=CC2=CC=CC=C12)* 0.000 title abstract 2
- 238000000034 method Methods 0.000 title description 23
- 230000008569 process Effects 0.000 title description 5
- 150000001875 compounds Chemical class 0.000 claims abstract description 183
- 150000003839 salts Chemical class 0.000 claims abstract description 17
- 239000000262 estrogen Substances 0.000 claims abstract description 15
- 229940011871 estrogen Drugs 0.000 claims abstract description 14
- 208000001132 Osteoporosis Diseases 0.000 claims abstract description 6
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 4
- 201000011510 cancer Diseases 0.000 claims abstract description 4
- 208000029078 coronary artery disease Diseases 0.000 claims abstract description 4
- 230000001419 dependent effect Effects 0.000 claims abstract description 4
- 239000003814 drug Substances 0.000 claims abstract description 4
- 230000007170 pathology Effects 0.000 claims abstract description 4
- 230000002265 prevention Effects 0.000 claims abstract description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 42
- 125000002252 acyl group Chemical group 0.000 claims description 25
- -1 O-R3 wherein R3 is H Chemical group 0.000 claims description 21
- 125000005843 halogen group Chemical group 0.000 claims description 18
- 125000003545 alkoxy group Chemical group 0.000 claims description 15
- 125000003118 aryl group Chemical group 0.000 claims description 14
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 14
- 125000001424 substituent group Chemical group 0.000 claims description 12
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 12
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 11
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 10
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims description 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 10
- 125000004429 atom Chemical group 0.000 claims description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 9
- 125000003342 alkenyl group Chemical group 0.000 claims description 8
- 125000000262 haloalkenyl group Chemical group 0.000 claims description 8
- 125000001188 haloalkyl group Chemical group 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 7
- 125000004432 carbon atom Chemical group C* 0.000 claims description 7
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
- IQVYMVBVNVNDLK-UHFFFAOYSA-N C=1COC2=CC=CC=C2C=1CC1=CC=CC=C1 Chemical compound C=1COC2=CC=CC=C2C=1CC1=CC=CC=C1 IQVYMVBVNVNDLK-UHFFFAOYSA-N 0.000 claims description 5
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 5
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 5
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 5
- 229910052731 fluorine Inorganic materials 0.000 claims description 5
- 239000011737 fluorine Substances 0.000 claims description 5
- 125000001624 naphthyl group Chemical group 0.000 claims description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims description 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 5
- 150000000463 2H-chromenes Chemical class 0.000 claims description 4
- 125000002861 (C1-C4) alkanoyl group Chemical group 0.000 claims description 3
- QKFSKKROTLEPHN-UHFFFAOYSA-N 3-phenyl-4-[[4-(2-piperidin-1-ylethoxy)phenyl]methyl]-2h-chromen-7-ol Chemical group C=1C=CC=CC=1C=1COC2=CC(O)=CC=C2C=1CC(C=C1)=CC=C1OCCN1CCCCC1 QKFSKKROTLEPHN-UHFFFAOYSA-N 0.000 claims description 3
- 125000005330 8 membered heterocyclic group Chemical group 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 2
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims description 2
- 229940099990 ogen Drugs 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 117
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 68
- 239000000243 solution Substances 0.000 description 67
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 58
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 53
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 39
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 35
- 239000000203 mixture Substances 0.000 description 35
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 33
- 235000019439 ethyl acetate Nutrition 0.000 description 28
- 239000007787 solid Substances 0.000 description 28
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 26
- 241000700159 Rattus Species 0.000 description 20
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 20
- 239000000047 product Substances 0.000 description 19
- 239000002904 solvent Substances 0.000 description 19
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 18
- 230000000694 effects Effects 0.000 description 18
- 239000003208 petroleum Substances 0.000 description 18
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 18
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 17
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 17
- 229960004622 raloxifene Drugs 0.000 description 17
- 229910000027 potassium carbonate Inorganic materials 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 210000000988 bone and bone Anatomy 0.000 description 13
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 13
- 239000003054 catalyst Substances 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 description 11
- XZEUAXYWNKYKPL-WDYNHAJCSA-N levormeloxifene Chemical compound C1([C@H]2[C@@H](C3=CC=C(C=C3OC2(C)C)OC)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 XZEUAXYWNKYKPL-WDYNHAJCSA-N 0.000 description 11
- 229950002728 levormeloxifene Drugs 0.000 description 11
- 238000009835 boiling Methods 0.000 description 10
- 125000006239 protecting group Chemical group 0.000 description 10
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 10
- 229960001701 chloroform Drugs 0.000 description 9
- 239000011777 magnesium Substances 0.000 description 9
- 235000015320 potassium carbonate Nutrition 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- 150000001562 benzopyrans Chemical group 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 8
- 239000000556 agonist Substances 0.000 description 7
- 239000002585 base Substances 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 6
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 6
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 6
- 235000011114 ammonium hydroxide Nutrition 0.000 description 6
- 239000003480 eluent Substances 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 230000003389 potentiating effect Effects 0.000 description 6
- 229940095743 selective estrogen receptor modulator Drugs 0.000 description 6
- 239000000333 selective estrogen receptor modulator Substances 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- 210000004291 uterus Anatomy 0.000 description 6
- 206010065687 Bone loss Diseases 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- SUSQOBVLVYHIEX-UHFFFAOYSA-N o-phenylene-diaceto-nitrile Natural products N#CCC1=CC=CC=C1 SUSQOBVLVYHIEX-UHFFFAOYSA-N 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 239000008259 solid foam Substances 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 229960001603 tamoxifen Drugs 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 4
- 238000003747 Grignard reaction Methods 0.000 description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 230000003042 antagnostic effect Effects 0.000 description 4
- 239000000010 aprotic solvent Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- 229960005309 estradiol Drugs 0.000 description 4
- 229930182833 estradiol Natural products 0.000 description 4
- 238000003818 flash chromatography Methods 0.000 description 4
- 239000012458 free base Substances 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- 229910052749 magnesium Inorganic materials 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 235000010755 mineral Nutrition 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 238000006722 reduction reaction Methods 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- VFLQQZCRHPIGJU-UHFFFAOYSA-N 1-(2-chloroethyl)piperidine;hydron;chloride Chemical compound Cl.ClCCN1CCCCC1 VFLQQZCRHPIGJU-UHFFFAOYSA-N 0.000 description 3
- PGZVFRAEAAXREB-UHFFFAOYSA-N 2,2-dimethylpropanoyl 2,2-dimethylpropanoate Chemical compound CC(C)(C)C(=O)OC(=O)C(C)(C)C PGZVFRAEAAXREB-UHFFFAOYSA-N 0.000 description 3
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- KYNSBQPICQTCGU-UHFFFAOYSA-N Benzopyrane Chemical class C1=CC=C2C=CCOC2=C1 KYNSBQPICQTCGU-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 210000004705 lumbosacral region Anatomy 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 229940087646 methanolamine Drugs 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 150000002989 phenols Chemical class 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- UYQPSKUPEXAQRJ-UHFFFAOYSA-N 1-(chloromethyl)-4-phenylmethoxybenzene Chemical compound C1=CC(CCl)=CC=C1OCC1=CC=CC=C1 UYQPSKUPEXAQRJ-UHFFFAOYSA-N 0.000 description 2
- SSIMHHUMYMHNID-UHFFFAOYSA-N 4-(chloromethyl)phenol Chemical compound OC1=CC=C(CCl)C=C1 SSIMHHUMYMHNID-UHFFFAOYSA-N 0.000 description 2
- WPJWYDWRUYBVGA-UHFFFAOYSA-N 4-benzylidene-2,3-dihydrochromene Chemical compound C12=CC=CC=C2OCCC1=CC1=CC=CC=C1 WPJWYDWRUYBVGA-UHFFFAOYSA-N 0.000 description 2
- PJJGZPJJTHBVMX-UHFFFAOYSA-N 5,7-Dihydroxyisoflavone Chemical compound C=1C(O)=CC(O)=C(C2=O)C=1OC=C2C1=CC=CC=C1 PJJGZPJJTHBVMX-UHFFFAOYSA-N 0.000 description 2
- FSCQILCMJJOHDG-UHFFFAOYSA-N 5-hydroxy-7-methoxy-3-phenyl-2,3-dihydrochromen-4-one Chemical compound C1OC2=CC(OC)=CC(O)=C2C(=O)C1C1=CC=CC=C1 FSCQILCMJJOHDG-UHFFFAOYSA-N 0.000 description 2
- WMKOZARWBMFKAS-UHFFFAOYSA-N 7-hydroxyisoflavone Chemical compound C=1C(O)=CC=C(C2=O)C=1OC=C2C1=CC=CC=C1 WMKOZARWBMFKAS-UHFFFAOYSA-N 0.000 description 2
- 108010092408 Eosinophil Peroxidase Proteins 0.000 description 2
- 102100028471 Eosinophil peroxidase Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 2
- 229910017974 NH40H Inorganic materials 0.000 description 2
- 235000019502 Orange oil Nutrition 0.000 description 2
- JPYHHZQJCSQRJY-UHFFFAOYSA-N Phloroglucinol Natural products CCC=CCC=CCC=CCC=CCCCCC(=O)C1=C(O)C=C(O)C=C1O JPYHHZQJCSQRJY-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000001266 acyl halides Chemical class 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 150000001342 alkaline earth metals Chemical class 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000001833 anti-estrogenic effect Effects 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- WUADCCWRTIWANL-UHFFFAOYSA-N biochanin A Chemical compound C1=CC(OC)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O WUADCCWRTIWANL-UHFFFAOYSA-N 0.000 description 2
- 230000005587 bubbling Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000003821 enantio-separation Methods 0.000 description 2
- 230000002327 eosinophilic effect Effects 0.000 description 2
- 102000015694 estrogen receptors Human genes 0.000 description 2
- 108010038795 estrogen receptors Proteins 0.000 description 2
- 230000001076 estrogenic effect Effects 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000002198 insoluble material Substances 0.000 description 2
- 150000004658 ketimines Chemical class 0.000 description 2
- 231100000636 lethal dose Toxicity 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 239000010502 orange oil Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 102000013415 peroxidase activity proteins Human genes 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- QCDYQQDYXPDABM-UHFFFAOYSA-N phloroglucinol Chemical compound OC1=CC(O)=CC(O)=C1 QCDYQQDYXPDABM-UHFFFAOYSA-N 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 238000007514 turning Methods 0.000 description 2
- 238000002525 ultrasonication Methods 0.000 description 2
- 230000001836 utereotrophic effect Effects 0.000 description 2
- BBDAZCQYDACEAP-UHFFFAOYSA-N (2-hydroxy-3,4-dihydro-2H-chromen-7-yl) 2,2-dimethylpropanoate Chemical compound OC1OC2=CC(=CC=C2CC1)OC(C(C)(C)C)=O BBDAZCQYDACEAP-UHFFFAOYSA-N 0.000 description 1
- NIIVBDSTHWZTJC-UHFFFAOYSA-N (4-oxo-3-phenyl-2,3-dihydrochromen-7-yl) 2,2-dimethylpropanoate Chemical compound C1OC2=CC(OC(=O)C(C)(C)C)=CC=C2C(=O)C1C1=CC=CC=C1 NIIVBDSTHWZTJC-UHFFFAOYSA-N 0.000 description 1
- HBWSXWRFMUSIQF-UHFFFAOYSA-N (4-oxo-3-phenylchromen-7-yl) 2,2-dimethylpropanoate Chemical compound C=1C(OC(=O)C(C)(C)C)=CC=C(C2=O)C=1OC=C2C1=CC=CC=C1 HBWSXWRFMUSIQF-UHFFFAOYSA-N 0.000 description 1
- YYFZIHWSVCQGLR-UHFFFAOYSA-N (5-hydroxy-4-oxo-3-phenyl-2,3-dihydrochromen-7-yl) 2,2-dimethylpropanoate Chemical compound C1OC2=CC(OC(=O)C(C)(C)C)=CC(O)=C2C(=O)C1C1=CC=CC=C1 YYFZIHWSVCQGLR-UHFFFAOYSA-N 0.000 description 1
- YWABDXBMWCXDNY-UHFFFAOYSA-N (5-hydroxy-4-oxo-3-phenylchromen-7-yl) 2,2-dimethylpropanoate Chemical compound C=1C(OC(=O)C(C)(C)C)=CC(O)=C(C2=O)C=1OC=C2C1=CC=CC=C1 YWABDXBMWCXDNY-UHFFFAOYSA-N 0.000 description 1
- SEPPVOUBHWNCAW-FNORWQNLSA-N (E)-4-oxonon-2-enal Chemical compound CCCCCC(=O)\C=C\C=O SEPPVOUBHWNCAW-FNORWQNLSA-N 0.000 description 1
- KEIFWROAQVVDBN-UHFFFAOYSA-N 1,2-dihydronaphthalene Chemical compound C1=CC=C2C=CCCC2=C1 KEIFWROAQVVDBN-UHFFFAOYSA-N 0.000 description 1
- PDUKJODPFIFHNK-UHFFFAOYSA-N 1-[2-(4-bromophenoxy)ethyl]piperidine Chemical compound C1=CC(Br)=CC=C1OCCN1CCCCC1 PDUKJODPFIFHNK-UHFFFAOYSA-N 0.000 description 1
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
- JHQBLYITVCBGTO-UHFFFAOYSA-N 2-(4-fluorophenyl)acetonitrile Chemical compound FC1=CC=C(CC#N)C=C1 JHQBLYITVCBGTO-UHFFFAOYSA-N 0.000 description 1
- MFYSUUPKMDJYPF-UHFFFAOYSA-N 2-[(4-methyl-2-nitrophenyl)diazenyl]-3-oxo-n-phenylbutanamide Chemical compound C=1C=CC=CC=1NC(=O)C(C(=O)C)N=NC1=CC=C(C)C=C1[N+]([O-])=O MFYSUUPKMDJYPF-UHFFFAOYSA-N 0.000 description 1
- HQALDKFFRYFTKP-UHFFFAOYSA-N 2-[4-[4-(2-benzyl-1-benzothiophen-3-yl)phenyl]-2-bromo-6-(3-methoxyphenyl)phenoxy]acetic acid Chemical compound COC1=CC=CC(C=2C(=C(Br)C=C(C=2)C=2C=CC(=CC=2)C=2C3=CC=CC=C3SC=2CC=2C=CC=CC=2)OCC(O)=O)=C1 HQALDKFFRYFTKP-UHFFFAOYSA-N 0.000 description 1
- VADKRMSMGWJZCF-UHFFFAOYSA-N 2-bromophenol Chemical compound OC1=CC=CC=C1Br VADKRMSMGWJZCF-UHFFFAOYSA-N 0.000 description 1
- DGMOBVGABMBZSB-UHFFFAOYSA-N 2-methylpropanoyl chloride Chemical compound CC(C)C(Cl)=O DGMOBVGABMBZSB-UHFFFAOYSA-N 0.000 description 1
- SLHBRIIHMDJIBT-UHFFFAOYSA-N 2-phenyl-1-(2,4,6-trihydroxyphenyl)ethanone Chemical compound OC1=CC(O)=CC(O)=C1C(=O)CC1=CC=CC=C1 SLHBRIIHMDJIBT-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- HYRGVNMFNQBLQO-UHFFFAOYSA-N 3,4-dihydrochromene-2,2-diol Chemical compound C1=CC=C2OC(O)(O)CCC2=C1 HYRGVNMFNQBLQO-UHFFFAOYSA-N 0.000 description 1
- LLBZPESJRQGYMB-UHFFFAOYSA-N 4-one Natural products O1C(C(=O)CC)CC(C)C11C2(C)CCC(C3(C)C(C(C)(CO)C(OC4C(C(O)C(O)C(COC5C(C(O)C(O)CO5)OC5C(C(OC6C(C(O)C(O)C(CO)O6)O)C(O)C(CO)O5)OC5C(C(O)C(O)C(C)O5)O)O4)O)CC3)CC3)=C3C2(C)CC1 LLBZPESJRQGYMB-UHFFFAOYSA-N 0.000 description 1
- RWWWQYIIBUAUFH-UHFFFAOYSA-N 7-methoxy-3-phenyl-4-[4-(2-piperidin-1-ylethoxy)phenyl]-2,3-dihydrochromene-4,5-diol;hydrochloride Chemical compound Cl.C=1C(OC)=CC(O)=C(C2(O)C=3C=CC(OCCN4CCCCC4)=CC=3)C=1OCC2C1=CC=CC=C1 RWWWQYIIBUAUFH-UHFFFAOYSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- ZIIAFXZZPAUVNI-UHFFFAOYSA-N Cl.C1=2C(OC(C)C)=CC(OC(=O)C(C)(C)C)=CC=2OCC(C=2C=CC(OC(=O)C(C)(C)C)=CC=2)=C1C(C=C1)=CC=C1OCCN1CCCCC1 Chemical compound Cl.C1=2C(OC(C)C)=CC(OC(=O)C(C)(C)C)=CC=2OCC(C=2C=CC(OC(=O)C(C)(C)C)=CC=2)=C1C(C=C1)=CC=C1OCCN1CCCCC1 ZIIAFXZZPAUVNI-UHFFFAOYSA-N 0.000 description 1
- YEBBDLZAXWSHBW-UHFFFAOYSA-N Cl.C1=2C(OC)=CC(OC(=O)C(C)(C)C)=CC=2OCC(C=2C=CC=CC=2)=C1C(C=C1)=CC=C1OCCN1CCCCC1 Chemical compound Cl.C1=2C(OC)=CC(OC(=O)C(C)(C)C)=CC=2OCC(C=2C=CC=CC=2)=C1C(C=C1)=CC=C1OCCN1CCCCC1 YEBBDLZAXWSHBW-UHFFFAOYSA-N 0.000 description 1
- GLCIBNUSGZCJLD-UHFFFAOYSA-N Cl.C1=CC(OC(=O)C(C)(C)C)=CC=C1C(COC1=CC(OC(=O)C(C)(C)C)=CC(O)=C11)=C1C(C=C1)=CC=C1OCCN1CCCCC1 Chemical compound Cl.C1=CC(OC(=O)C(C)(C)C)=CC=C1C(COC1=CC(OC(=O)C(C)(C)C)=CC(O)=C11)=C1C(C=C1)=CC=C1OCCN1CCCCC1 GLCIBNUSGZCJLD-UHFFFAOYSA-N 0.000 description 1
- SKSTYWNLELRPSI-UHFFFAOYSA-N Cl.C1=CC(OC)=CC=C1C(COC1=CC(O)=CC(O)=C11)=C1C(C=C1)=CC=C1OCCN1CCCCC1 Chemical compound Cl.C1=CC(OC)=CC=C1C(COC1=CC(O)=CC(O)=C11)=C1C(C=C1)=CC=C1OCCN1CCCCC1 SKSTYWNLELRPSI-UHFFFAOYSA-N 0.000 description 1
- HDNRCRRIWUIJCB-UHFFFAOYSA-N Cl.C1=CC(OC)=CC=C1C(COC1=CC(OC(=O)C(C)(C)C)=CC(O)=C11)=C1C(C=C1)=CC=C1OCCN1CCCCC1 Chemical compound Cl.C1=CC(OC)=CC=C1C(COC1=CC(OC(=O)C(C)(C)C)=CC(O)=C11)=C1C(C=C1)=CC=C1OCCN1CCCCC1 HDNRCRRIWUIJCB-UHFFFAOYSA-N 0.000 description 1
- AMHCKPXCBQCBHJ-UHFFFAOYSA-N Cl.C1OC2=CC(O)=CC(O)=C2C(C=2C=CC(OCCN3CCCCC3)=CC=2)=C1C1=CC=CC=C1 Chemical compound Cl.C1OC2=CC(O)=CC(O)=C2C(C=2C=CC(OCCN3CCCCC3)=CC=2)=C1C1=CC=CC=C1 AMHCKPXCBQCBHJ-UHFFFAOYSA-N 0.000 description 1
- CVETVNVUQJLVSM-UHFFFAOYSA-N Cl.C1OC2=CC(OC(=O)C(C)(C)C)=CC(O)=C2C(C=2C=CC(OCCN3CCCCC3)=CC=2)=C1C1=CC=C(F)C=C1 Chemical compound Cl.C1OC2=CC(OC(=O)C(C)(C)C)=CC(O)=C2C(C=2C=CC(OCCN3CCCCC3)=CC=2)=C1C1=CC=C(F)C=C1 CVETVNVUQJLVSM-UHFFFAOYSA-N 0.000 description 1
- QGCUPSZBXDSVLF-UHFFFAOYSA-N Cl.C1OC2=CC(OC(=O)C)=CC(OC(C)=O)=C2C(C=2C=CC(OCCN3CCCCC3)=CC=2)=C1C1=CC=CC=C1 Chemical compound Cl.C1OC2=CC(OC(=O)C)=CC(OC(C)=O)=C2C(C=2C=CC(OCCN3CCCCC3)=CC=2)=C1C1=CC=CC=C1 QGCUPSZBXDSVLF-UHFFFAOYSA-N 0.000 description 1
- YRLHDKZGAHIFAL-UHFFFAOYSA-N Cl.C1OC2=CC(OC)=CC(O)=C2C(C=2C=CC(OCCN3CCCCC3)=CC=2)=C1C1=CC=CC=C1 Chemical compound Cl.C1OC2=CC(OC)=CC(O)=C2C(C=2C=CC(OCCN3CCCCC3)=CC=2)=C1C1=CC=CC=C1 YRLHDKZGAHIFAL-UHFFFAOYSA-N 0.000 description 1
- RWGRPTBDSWZJQB-UHFFFAOYSA-N Cl.C=1C(OC(=O)C(C)(C)C)=CC(O)=C(C2(O)C=3C=CC(OCCN4CCCCC4)=CC=3)C=1OCC2C1=CC=CC=C1 Chemical compound Cl.C=1C(OC(=O)C(C)(C)C)=CC(O)=C(C2(O)C=3C=CC(OCCN4CCCCC4)=CC=3)C=1OCC2C1=CC=CC=C1 RWGRPTBDSWZJQB-UHFFFAOYSA-N 0.000 description 1
- TUYZVNDITPMEFI-UHFFFAOYSA-N Cl.C=1C=CC=CC=1C=1COC2=CC(OC(=O)C(C)(C)C)=CC=C2C=1CC(C=C1)=CC=C1OCCN1CCCCC1 Chemical compound Cl.C=1C=CC=CC=1C=1COC2=CC(OC(=O)C(C)(C)C)=CC=C2C=1CC(C=C1)=CC=C1OCCN1CCCCC1 TUYZVNDITPMEFI-UHFFFAOYSA-N 0.000 description 1
- UHYMFGHWIMTYRI-UHFFFAOYSA-N Cl.C=1C=CC=CC=1C=1COC2=CC(OC(=O)C(C)C)=CC=C2C=1CC(C=C1)=CC=C1OCCN1CCCCC1 Chemical compound Cl.C=1C=CC=CC=1C=1COC2=CC(OC(=O)C(C)C)=CC=C2C=1CC(C=C1)=CC=C1OCCN1CCCCC1 UHYMFGHWIMTYRI-UHFFFAOYSA-N 0.000 description 1
- 101000882584 Homo sapiens Estrogen receptor Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 229910010084 LiAlH4 Inorganic materials 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- MKYQPGPNVYRMHI-UHFFFAOYSA-N Triphenylethylene Chemical group C=1C=CC=CC=1C=C(C=1C=CC=CC=1)C1=CC=CC=C1 MKYQPGPNVYRMHI-UHFFFAOYSA-N 0.000 description 1
- JJPSLYWPZOZHKQ-UHFFFAOYSA-N [3-(4-methoxyphenyl)-4-oxo-2,3-dihydrochromen-7-yl] 2,2-dimethylpropanoate Chemical compound C1=CC(OC)=CC=C1C1C(=O)C2=CC=C(OC(=O)C(C)(C)C)C=C2OC1 JJPSLYWPZOZHKQ-UHFFFAOYSA-N 0.000 description 1
- AJDUZBPZZMWNBB-UHFFFAOYSA-N [3-(4-methoxyphenyl)-4-oxochromen-7-yl] 2,2-dimethylpropanoate Chemical compound C1=CC(OC)=CC=C1C1=COC2=CC(OC(=O)C(C)(C)C)=CC=C2C1=O AJDUZBPZZMWNBB-UHFFFAOYSA-N 0.000 description 1
- LHSHTYLEVOVYOR-UHFFFAOYSA-N [4,5-dihydroxy-3-(4-methoxyphenyl)-4-[4-(2-piperidin-1-ylethoxy)phenyl]-2,3-dihydrochromen-7-yl] 2,2-dimethylpropanoate;hydrochloride Chemical compound Cl.C1=CC(OC)=CC=C1C1C(C=2C=CC(OCCN3CCCCC3)=CC=2)(O)C2=C(O)C=C(OC(=O)C(C)(C)C)C=C2OC1 LHSHTYLEVOVYOR-UHFFFAOYSA-N 0.000 description 1
- IEDOVTQTGQKHOI-UHFFFAOYSA-N [4-[7-(2,2-dimethylpropanoyloxy)-4,5-dihydroxy-4-[4-(2-piperidin-1-ylethoxy)phenyl]-2,3-dihydrochromen-3-yl]phenyl] 2,2-dimethylpropanoate Chemical compound C1=CC(OC(=O)C(C)(C)C)=CC=C1C1C(C=2C=CC(OCCN3CCCCC3)=CC=2)(O)C2=C(O)C=C(OC(=O)C(C)(C)C)C=C2OC1 IEDOVTQTGQKHOI-UHFFFAOYSA-N 0.000 description 1
- MHZFGMCDYUUIBJ-UHFFFAOYSA-N [4-[7-(2,2-dimethylpropanoyloxy)-5-hydroxy-4-[4-(2-piperidin-1-ylethoxy)phenyl]-3,4-dihydro-2h-chromen-3-yl]phenyl] 2,2-dimethylpropanoate;hydrochloride Chemical compound Cl.C1=CC(OC(=O)C(C)(C)C)=CC=C1C1C(C=2C=CC(OCCN3CCCCC3)=CC=2)C2=C(O)C=C(OC(=O)C(C)(C)C)C=C2OC1 MHZFGMCDYUUIBJ-UHFFFAOYSA-N 0.000 description 1
- OCUIUJZUXNLSQT-UHFFFAOYSA-N [4-[7-(2,2-dimethylpropanoyloxy)-5-hydroxy-4-oxo-2,3-dihydrochromen-3-yl]phenyl] 2,2-dimethylpropanoate Chemical compound C1=CC(OC(=O)C(C)(C)C)=CC=C1C1C(=O)C2=C(O)C=C(OC(=O)C(C)(C)C)C=C2OC1 OCUIUJZUXNLSQT-UHFFFAOYSA-N 0.000 description 1
- WLLIDIRIQIVYDY-UHFFFAOYSA-N [4-hydroxy-3-(4-methoxyphenyl)-4-[(4-phenylmethoxyphenyl)methyl]-2,3-dihydrochromen-7-yl] 2,2-dimethylpropanoate Chemical compound C1=CC(OC)=CC=C1C1C(CC=2C=CC(OCC=3C=CC=CC=3)=CC=2)(O)C2=CC=C(OC(=O)C(C)(C)C)C=C2OC1 WLLIDIRIQIVYDY-UHFFFAOYSA-N 0.000 description 1
- DVTHEVJDWHECGG-UHFFFAOYSA-N [4-hydroxy-4-[(4-hydroxyphenyl)methyl]-3-(4-methoxyphenyl)-2,3-dihydrochromen-7-yl] 2,2-dimethylpropanoate Chemical compound C1=CC(OC)=CC=C1C1C(CC=2C=CC(O)=CC=2)(O)C2=CC=C(OC(=O)C(C)(C)C)C=C2OC1 DVTHEVJDWHECGG-UHFFFAOYSA-N 0.000 description 1
- OVFRGUBNSIYVIR-UHFFFAOYSA-N [5-hydroxy-3-(4-methoxyphenyl)-4-oxo-2,3-dihydrochromen-7-yl] 2,2-dimethylpropanoate Chemical compound C1=CC(OC)=CC=C1C1C(=O)C2=C(O)C=C(OC(=O)C(C)(C)C)C=C2OC1 OVFRGUBNSIYVIR-UHFFFAOYSA-N 0.000 description 1
- UMEAZEUAZOQCDG-UHFFFAOYSA-N [5-hydroxy-3-(4-methoxyphenyl)-4-oxochromen-7-yl] 2,2-dimethylpropanoate Chemical compound C1=CC(OC)=CC=C1C1=COC2=CC(OC(=O)C(C)(C)C)=CC(O)=C2C1=O UMEAZEUAZOQCDG-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001348 alkyl chlorides Chemical class 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001395 anti-uterotrophic effect Effects 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Inorganic materials [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 1
- 150000007962 benzene acetonitriles Chemical class 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- VZWXIQHBIQLMPN-UHFFFAOYSA-N chromane Chemical compound C1=CC=C2CCCOC2=C1 VZWXIQHBIQLMPN-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000004821 effect on bone Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- HKQYGTCOTHHOMP-UHFFFAOYSA-N formononetin Chemical compound C1=CC(OC)=CC=C1C1=COC2=CC(O)=CC=C2C1=O HKQYGTCOTHHOMP-UHFFFAOYSA-N 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 1
- SLRCCWJSBJZJBV-BYNSBNAKSA-N genisteine Chemical compound C1N2CCCC[C@@H]2[C@@H]2CN3CCCC[C@@H]3[C@H]1C2 SLRCCWJSBJZJBV-BYNSBNAKSA-N 0.000 description 1
- 150000004795 grignard reagents Chemical class 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- FMKOJHQHASLBPH-UHFFFAOYSA-N isopropyl iodide Chemical compound CC(C)I FMKOJHQHASLBPH-UHFFFAOYSA-N 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- XZEUAXYWNKYKPL-URLMMPGGSA-N ormeloxifene Chemical compound C1([C@@H]2[C@H](C3=CC=C(C=C3OC2(C)C)OC)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 XZEUAXYWNKYKPL-URLMMPGGSA-N 0.000 description 1
- 229960003327 ormeloxifene Drugs 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 210000003049 pelvic bone Anatomy 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 229960001553 phloroglucinol Drugs 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 230000036515 potency Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 229960003598 promazine Drugs 0.000 description 1
- 125000002112 pyrrolidino group Chemical group [*]N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229910052703 rhodium Inorganic materials 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 231100000161 signs of toxicity Toxicity 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003509 tertiary alcohols Chemical class 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01101521A EP1229036B1 (en) | 2001-01-24 | 2001-01-24 | 2H-1-benzopyran derivatives, processes for their preparation and pharmaceutical compositions thereof |
| EP01118682A EP1281710A1 (en) | 2001-08-03 | 2001-08-03 | 2H-1-benzopyran derivatives, processes for their preparation and pharmaceutical compositions thereof |
| PCT/EP2002/000567 WO2002059113A1 (en) | 2001-01-24 | 2002-01-21 | 2h-1-benzopyran derivatives, processes for their preparation and pharmaceutical compositions thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ527144A true NZ527144A (en) | 2005-03-24 |
Family
ID=26076450
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ527144A NZ527144A (en) | 2001-01-24 | 2002-01-21 | 2H-1-benzopyran derivatives, processes for their preparation and pharmaceutical compositions thereof |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US6951883B2 (enExample) |
| EP (1) | EP1355906B1 (enExample) |
| JP (1) | JP4332349B2 (enExample) |
| CN (1) | CN1261431C (enExample) |
| AT (1) | ATE286894T1 (enExample) |
| AU (1) | AU2002237282B2 (enExample) |
| BR (1) | BR0207066A (enExample) |
| CA (1) | CA2435775A1 (enExample) |
| CZ (1) | CZ20032014A3 (enExample) |
| DE (1) | DE60202590T2 (enExample) |
| DK (1) | DK1355906T3 (enExample) |
| DZ (1) | DZ3459A1 (enExample) |
| EA (1) | EA006158B1 (enExample) |
| ES (1) | ES2236485T3 (enExample) |
| HU (1) | HUP0401018A3 (enExample) |
| IL (2) | IL157065A0 (enExample) |
| MA (1) | MA26982A1 (enExample) |
| MX (1) | MXPA03006505A (enExample) |
| NO (1) | NO327808B1 (enExample) |
| NZ (1) | NZ527144A (enExample) |
| PL (1) | PL365062A1 (enExample) |
| PT (1) | PT1355906E (enExample) |
| SI (1) | SI1355906T1 (enExample) |
| SK (1) | SK287086B6 (enExample) |
| TN (1) | TNSN03043A1 (enExample) |
| WO (1) | WO2002059113A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8080675B2 (en) | 2004-09-21 | 2011-12-20 | Marshall Edwards, Inc. | Chroman derivatives, medicaments and use in therapy |
| EP2436680B1 (en) * | 2004-09-21 | 2016-05-18 | Marshall Edwards, Inc. | Chroman derivatives, medicaments and use in therapy |
| CN101056868B (zh) | 2004-09-21 | 2012-05-02 | 马休爱德华兹股份有限公司 | 取代的苯并二氢吡喃衍生物、药物及其在治疗中的应用 |
| AU2005201855B2 (en) * | 2004-09-21 | 2012-03-29 | Marshall Edwards, Inc. | Chroman derived compounds and formulations thereof for use in therapy |
| JP4976649B2 (ja) * | 2004-09-21 | 2012-07-18 | マーシャル エドワーズ，インク． | 化合物 |
| ES2377073T3 (es) * | 2004-09-21 | 2012-03-22 | Marshall Edwards, Inc. | Derivados de cromano sustituidos, medicamentos y utilización en terapia |
| CN101444499B (zh) * | 2007-11-26 | 2012-12-05 | 湘北威尔曼制药股份有限公司 | 一种化合物及其组合物的新用途 |
| WO2012061409A1 (en) | 2010-11-01 | 2012-05-10 | Marshall Edwards, Inc. | Isoflavonoid compounds and methods for the treatment of cancer |
| EA031077B1 (ru) | 2013-06-19 | 2018-11-30 | Серагон Фармасьютикалз, Инк. | Модулятор рецептора эстрогена и его применения |
| PT3253208T (pt) | 2015-02-02 | 2021-06-17 | The Spanish National Cancer Res Centre | Terapêuticas de combinação para utilização no tratamento do cancro da mama |
| EP3541809B1 (en) * | 2016-11-17 | 2025-06-25 | Sanofi | Novel substituted n-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof |
| WO2019051562A1 (en) * | 2017-09-15 | 2019-03-21 | Norbio No. 1 Pty Ltd | TREATMENT OF EXCITOTOXICITY |
| CN112225716A (zh) * | 2020-10-30 | 2021-01-15 | 陕西嘉禾生物科技股份有限公司 | 一种鹰嘴豆牙素a的合成方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3374245A (en) * | 1964-04-01 | 1968-03-19 | Ciba Geigy Corp | Unsaturated oxacycles |
| DE1518002C3 (de) * | 1965-01-02 | 1975-01-23 | Merck Patent Gmbh, 6100 Darmstadt | Isoflavane und Isoflavene und Verfahren zu Ihrer Herstellung sowie diese enthaltende Arzneimittel |
| US5280040A (en) * | 1993-03-11 | 1994-01-18 | Zymogenetics, Inc. | Methods for reducing bone loss using centchroman derivatives |
| US5985306A (en) * | 1996-10-28 | 1999-11-16 | Novo Nordisk A/S | (+)-enantiomers of cis-3,4-chroman derivatives useful in prevention or treatment of estrogen diseases or syndromes |
| IL129623A0 (en) * | 1996-10-28 | 2000-02-29 | Novo Nordisk As | Novel trans-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes |
| ATE225782T1 (de) | 1996-12-13 | 2002-10-15 | Chugai Pharmaceutical Co Ltd | Benzopyranderivate |
| KR20000001793A (ko) | 1998-06-13 | 2000-01-15 | 이경하 | 신규한 벤조피란 또는 티오벤조피란 유도체 |
| ES2207982T3 (es) | 1998-12-30 | 2004-06-01 | Signal Pharmaceuticals, Inc. | Compuestos y metodos para la modulacion de receptores estrogenicos. |
-
2002
- 2002-01-21 WO PCT/EP2002/000567 patent/WO2002059113A1/en not_active Ceased
- 2002-01-21 ES ES02703564T patent/ES2236485T3/es not_active Expired - Lifetime
- 2002-01-21 PL PL02365062A patent/PL365062A1/xx not_active IP Right Cessation
- 2002-01-21 JP JP2002559415A patent/JP4332349B2/ja not_active Expired - Fee Related
- 2002-01-21 BR BR0207066-9A patent/BR0207066A/pt not_active IP Right Cessation
- 2002-01-21 CN CNB02804066XA patent/CN1261431C/zh not_active Expired - Fee Related
- 2002-01-21 PT PT02703564T patent/PT1355906E/pt unknown
- 2002-01-21 SI SI200230096T patent/SI1355906T1/xx unknown
- 2002-01-21 DK DK02703564T patent/DK1355906T3/da active
- 2002-01-21 EA EA200300727A patent/EA006158B1/ru not_active IP Right Cessation
- 2002-01-21 CA CA002435775A patent/CA2435775A1/en not_active Abandoned
- 2002-01-21 US US10/466,118 patent/US6951883B2/en not_active Expired - Fee Related
- 2002-01-21 EP EP02703564A patent/EP1355906B1/en not_active Expired - Lifetime
- 2002-01-21 SK SK939-2003A patent/SK287086B6/sk not_active IP Right Cessation
- 2002-01-21 MX MXPA03006505A patent/MXPA03006505A/es active IP Right Grant
- 2002-01-21 AU AU2002237282A patent/AU2002237282B2/en not_active Ceased
- 2002-01-21 NZ NZ527144A patent/NZ527144A/en unknown
- 2002-01-21 DZ DZ023459A patent/DZ3459A1/fr active
- 2002-01-21 IL IL15706502A patent/IL157065A0/xx unknown
- 2002-01-21 CZ CZ20032014A patent/CZ20032014A3/cs unknown
- 2002-01-21 DE DE60202590T patent/DE60202590T2/de not_active Expired - Lifetime
- 2002-01-21 HU HU0401018A patent/HUP0401018A3/hu unknown
- 2002-01-21 AT AT02703564T patent/ATE286894T1/de not_active IP Right Cessation
-
2003
- 2003-07-08 TN TNPCT/EP2002/000567A patent/TNSN03043A1/en unknown
- 2003-07-15 MA MA27236A patent/MA26982A1/fr unknown
- 2003-07-23 NO NO20033318A patent/NO327808B1/no not_active IP Right Cessation
- 2003-07-23 IL IL157065A patent/IL157065A/en not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002237282B2 (en) | 2H-1-Benzopyran derivatives, processes for their preparation and pharmaceutical compositions thereof | |
| US6844336B2 (en) | 4-fluoroalkyl-2h-benzopyrans with anti-estogenic activity | |
| AU2002237282A1 (en) | 2H-1-Benzopyran derivatives, processes for their preparation and pharmaceutical compositions thereof | |
| EP1025096B1 (en) | Substituted chroman derivatives | |
| EP2826774A1 (en) | Intermediates for 6-substituted phenoxychroman carboxylic acid derivatives | |
| EP1229036B1 (en) | 2H-1-benzopyran derivatives, processes for their preparation and pharmaceutical compositions thereof | |
| US6043269A (en) | cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes | |
| JP2001502708A (ja) | エストロゲン関連の疾患または症候群の予防または治療に有用な新規なシス―３，４―クロマン誘導体 | |
| US5994390A (en) | Trans-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes | |
| Gauthier et al. | Synthesis and structure–activity relationships of analogs of EM-652 (acolbifene), a pure selective estrogen receptor modulator. Study of nitrogen substitution | |
| EP0937062B1 (en) | Novel cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes | |
| AU744403B2 (en) | Novel trans-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes | |
| CA2270113A1 (en) | Novel cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes | |
| HK1060558B (en) | 2h-1-benzopyran derivatives, processes for their preparation and pharmaceutical compositions thereof | |
| EP1281710A1 (en) | 2H-1-benzopyran derivatives, processes for their preparation and pharmaceutical compositions thereof | |
| JP2007516155A (ja) | エストロゲン活性を有する（３ｒ，４ｒ）−トランス−３，４−ジアリールクロマン誘導体 | |
| US20010021710A1 (en) | Novel cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes | |
| AU9733501A (en) | Novel cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes | |
| CZ2000948A3 (cs) | Substituované chromanové deriváty | |
| HK1075893B (en) | Compounds and methods for modulation of estrogen receptors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| S38A | Application for proceedings under section 38 (amendment of specification with leave of commissioner) |
Free format text: BY WAY OF CORRECTION AND EXPLANATION |
|
| PSEA | Patent sealed | ||
| S38C | Proceedings under section 38 (amendment of specification with leave of commissioner): specification amended | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) |